When treating any condition, there is always a risk of unwanted side effects. But when it comes to treatments for schizophrenia and the use of antipsychotic medication, research is increasingly showing that treatment may elevate the risk of metabolic syndromes and heart disease.
Smokers with certain high-risk genetic variants find it more difficult to quit smoking but are more likely to respond to cessation pharmacotherapy.
Short-term exposure to low levels of secondhand smoke (SHS) results in a concentration-dependent decrease in endothelial function.
Smokers with a new diagnosis of bladder cancer are significantly more likely to quit compared with smokers in the general population.
The smoking cessation drug varenicline (VAR) may also reduce alcohol consumption in social drinkers by increasing alcohol's aversive effects.
For individuals who have quit smoking, use of nicotine replacement therapy (NRT) may not impact relapse rates.
The FDA has notified the public that the smoking cessation aid Chantix (varenicline; Pfizer) may be associated with a small, increased risk of certain cardiovascular events in patients with cardiovascular disease.
Drugs in the Pipeline
Orexigen Therapeutics announced positive results from its Phase 2b trial for Empatic (bupropion SR/zonisamide SR), its investigational combination drug for the treatment of obesity.
The FDA has approved Watson's over-the-counter nicotine polacrilex gum in coated fruit and cinnamon flavors, the generic equivalent of GlaxoSmithKline Consumer Healthcare's smoking cessation aid, Nicorette Fruit Chill and Cinnamon Surge Coated gums.
The FDA has notified healthcare professionals and patients that it has required manufacturers of varenicline (Chantix, from Pfizer) and bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL, and Zyban, from GlaxoSmithKline) to add new Boxed Warnings to the product labeling and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms.